Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates




  • In Business
  • 2019-02-22 00:00:12Z
  • By Zacks Equity Research
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates  

Nevro (NVRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -88.24%. A quarter ago, it was expected that this maker of an electrical implant that treats leg and back pain would post a loss of $0.30 per share when it actually produced a loss of $0.37, delivering a surprise of -23.33%.

Over the last four quarters, the company has not been able to surpass consensus EPS estimates.

Nevro, which belongs to the Zacks Medical - Instruments industry, posted revenues of $107.94 million for the quarter ended December 2018, surpassing the Zacks Consensus Estimate by 0.53%. This compares to year-ago revenues of $97.96 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Nevro shares have added about 24.6% since the beginning of the year versus the S&P 500's gain of 11.1%.

What's Next for Nevro?

While Nevro has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Nevro was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.23 on $96.88 million in revenues for the coming quarter and -$0.64 on $419.87 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Nevro Corp. (NVRO) : Free Stock Analysis Report

To read this article on Zacks.com click here.
COMMENTS

More Related News

Revlon (REV) Reports Q4 Loss, Misses Revenue Estimates
Revlon (REV) Reports Q4 Loss, Misses Revenue Estimates

Revlon (REV) delivered earnings and revenue surprises of -673.33% and -1.03%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for March 18th
New Strong Buy Stocks for March 18th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: SP Plus Corporation (SP): This company that provides parking management, ground transportation, baggage, and other ancillary services has seen the Zacks Consensus Estimate for its current year earnings increasing 0.8% over the last 60 days. SP Plus Corporation Price and Consensus SP Plus Corporation price-consensus-chart | SP Plus Corporation Quote Federal Signal Corporation (FSS): This company that designs, manufactures, and supplies a suite of products and integrated solutions for municipal, governmental, industrial, and commercial customers has seen the Zacks Consensus Estimate for its current year earnings...

Dover (DOV) Stock Up 28% YTD: What
Dover (DOV) Stock Up 28% YTD: What's Driving the Rally?

Forecast-topping earnings performance in the fourth quarter of 2018 and upbeat outlook for 2019 contribute to the run-up in Dover's (DOV) shares.

Why Is Agnico (AEM) Up 4.4% Since Last Earnings Report?
Why Is Agnico (AEM) Up 4.4% Since Last Earnings Report?

Agnico Eagle Tops Earnings and Sales Estimates in Q4 Agnico Eagle reported net loss of $393.7 million or $1.67 per share in fourth-quarter 2018, against net income of $37.5 million or 16 cents in the year-ago quarter. Results in the quarter were partly affected by impairment losses along with derivative losses on financial instruments and non-cash foreign currency translation losses on deferred tax liabilities and non-recurring tax adjustments. Notably, the company recorded hefty impairment losses of $389.7 million or $1.66 per share in the reported quarter.

Ameren (AEE) Up 5.8% Since Last Earnings Report: Can It Continue?
Ameren (AEE) Up 5.8% Since Last Earnings Report: Can It Continue?

Ameren Q4 Earnings Miss Estimates, Revenues Up Y/Y Ameren Corporation's fourth-quarter 2018 earnings of 28 cents per share from continuing operations missed the Zacks Consensus Estimate of 32 cents by 12.5%. The bottom line, however, improved when compared to a loss of 24 cents incurred in the year-ago quarter. The company generated 2018 adjusted earnings of $3.37 per share from continuing operations, which missed the Zacks Consensus Estimate of $3.41 by 1.2%.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business

facebook
Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.